Published in Hepatitis Weekly, November 16th, 2009
Boceprevir is an investigational HCV protease inhibitor. Phase III registration studies with boceprevir in treatment-naive HCV patients and patients who failed prior treatment have been fully enrolled and are expected to be completed in mid-2010.
Boceprevir response guided therapy utilizes a unique...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.